ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Importantly, BCR-ABL expression leads to the degradation of the IFNa receptor (IFNAR) by ubiquitination that could be counteracted by pretreatment of CML cells with imatinib, restoring IFNa sensitivity [26].